|
Drug firm Indoco Remedies on Monday said it has received approval from the US health regulator for blood thinning
drug Apixaban tablets.
The approved product is therapeutically equivalent to the reference listed drug Eliquis of Bristol-Myers Squibb.
The approved product is therapeutically equivalent to the reference listed drug Eliquis of Bristol-Myers Squibb.
In a regulatory filing, Indoco Remedies said it has received approval from the US Food and Drug Administration (USFDA) for
its abbreviated new drug application (ANDA) for Apixaban tablets in the strengths of 2.5 mg and 5 mg. Apixaban is an
anticoagulant, or blood thinner. It is used for patients with health problems caused by a blood clot.
Apixaban is an anticoagulant, or blood thinner. It is used for patients with health problems caused by a blood clot.
Quoting IMS June 2020 moving annual total data, Indoco Remedies said the US market size of Apixaban tablets is USD 11,037
million.
Shares of Indoco Remedies were trading 3.50 per cent higher at Rs 228.95 apiece on BSE. Shares of Indoco Remedies were
trading 3.50 per cent higher at Rs 228.95 apiece on BSE.
|
